Australia markets open in 4 hours 19 minutes

Zevra Therapeutics, Inc. (ZVRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.9000+0.0900 (+1.87%)
At close: 04:00PM EDT
4.9500 +0.05 (+1.02%)
After hours: 06:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 204.66M
Enterprise value 196.23M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.58
Price/book (mrq)4.19
Enterprise value/revenue 7.08
Enterprise value/EBITDA -2.02

Trading information

Stock price history

Beta (5Y monthly) 1.96
52-week change 3-3.54%
S&P500 52-week change 322.55%
52-week high 37.2800
52-week low 33.8900
50-day moving average 34.6985
200-day moving average 35.1639

Share statistics

Avg vol (3-month) 3225.93k
Avg vol (10-day) 3319.43k
Shares outstanding 541.85M
Implied shares outstanding 641.85M
Float 836.1M
% held by insiders 18.39%
% held by institutions 133.84%
Shares short (14 June 2024) 42.76M
Short ratio (14 June 2024) 416.25
Short % of float (14 June 2024) 46.63%
Short % of shares outstanding (14 June 2024) 46.61%
Shares short (prior month 15 May 2024) 42.68M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 328 Dec 2020
Ex-dividend date 4N/A
Last split factor 21:16
Last split date 328 Dec 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -178.47%
Operating margin (ttm)-598.13%

Management effectiveness

Return on assets (ttm)-27.75%
Return on equity (ttm)-82.27%

Income statement

Revenue (ttm)27.71M
Revenue per share (ttm)0.74
Quarterly revenue growth (yoy)7.80%
Gross profit (ttm)N/A
EBITDA -54.77M
Net income avi to common (ttm)-49.45M
Diluted EPS (ttm)-1.3200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)52.72M
Total cash per share (mrq)1.26
Total debt (mrq)44.29M
Total debt/equity (mrq)90.72%
Current ratio (mrq)2.10
Book value per share (mrq)1.17

Cash flow statement

Operating cash flow (ttm)-45.66M
Levered free cash flow (ttm)-14.47M